Beryl Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-279,478
Closed -$629K 256
2020
Q3
$629K Sell
279,478
-9,671,831
-97% -$27.6M 0.11% 76
2020
Q2
$35.6M Sell
9,951,309
-335,633
-3% -$1.21M 6.77% 4
2020
Q1
$39.1M Buy
10,286,942
+4,566,335
+80% +$15M 8.25% 5
2019
Q4
$17.2M Buy
+5,720,607
New +$14.9M 2.78% 15

Other funds holding BMY.RT

Beryl Capital Management's BMY.RT Position: Q4 2020 in Review

Beryl Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 279,478 shares — an estimated $629K sold.

Beryl Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $39.1M in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Beryl Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Beryl Capital Management sold 279,478 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $629K.
  • Beryl Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Beryl Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $39.1M in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Beryl Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.